## Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

NEW YORK, April 8, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( "PAVmed"), today announced that Lucid's President & Chief Operating Officer Shaun O'Neil will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Thursday, April 11, 2024, at 11:00 a.m. E.T.

The fireside chat will be webcast live and can be accessed by visiting the <u>Investor Relations Section</u> of the Lucid Diagnostics website or by clicking <u>here</u>. A replay of the webcast will be available on the website for 30 days following the conclusion of the live broadcast. Company management will meet with investors in one-on-one meetings during the conference.

## **About Lucid Diagnostics**

Lucid Diagnostics Inc. is a commercial-stage medical diagnostics company focused on cancer prevention, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard<sup>®</sup> Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck Esophageal Cell Collection Device, is the first and only commercially available diagnostic test capable of serving as a widespread screening tool for at-risk patients to mitigate the risks of cancer and cancer deaths through early detection of esophageal precancer.

For more information, please visit <u>www.luciddx.com</u> and for more information about its parent company PAVmed, please visit <u>www.pavmed.com</u>.

**SOURCE Lucid Diagnostics** 

For further information: Matt Riley, PAVmed and Lucid Diagnostics, 610.348.8926, mjr@pavmed.com

https://ir.pavmed.com/2024-04-08-Lucid-Diagnostics-to-Participate-in-Fireside-Chat-at-the-23rd-Annual-Needham-Virtual-Healthcare-Conference